The Business of Biotech: What to Do When the S*#t Hits the Fan

From CEO-itis to FDA-itis, the path of a biotech company is never dull. Whether the oft-repeated saying, “may you live in interesting times,” is a blessing or a curse depends entirely on your perspective. As a life science venture capital investor with close to 25 years of experience, I have encountered many unexpected and interesting … Continue reading The Business of Biotech: What to Do When the S*#t Hits the Fan